Hot Watch List: Pandora Media Inc (NYSE:P), Viking Therapeutics, Inc. (NASDAQ:VKTX), PAR Technology Corporation (NYSE:PAR), OvaScience, Inc. (NASDAQ:OVAS), Merck & Co. (NYSE:MRK)

On 13 July, Pandora Media Inc (NYSE:P) shares increased 1.53% and was closed at $15.28. P EPS growth in last 5 year was 0.00%. Pandora Media Inc (NYSE:P) year to date (YTD) performance is -14.30%. On 8 July, Pandora Media Inc (NYSE:P) has closed a deal to acquire music analytics provider Next Big Sound for an undisclosed sum. The deal puts the finishing touches on a plan to give the industry more data about artists and their fans.

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares remains unchanged in last trading session and ended the day at $6.95. On July 7, 2015, Viking Therapeutics, Inc. (NASDAQ:VKTX) entered into a Sublease (the “Sublease”) with Fish & Richardson P.C. (“Landlord”). The Sublease is for approximately 7,049 rentable square feet of space located at 12340 El Camino Real, Suite 250, San Diego, California 92130 (the “Premises”). The Premises will become the Company’s corporate headquarters.

On 13 July, PAR Technology Corporation (NYSE:PAR) shares decreased -1.81% and was closed at $4.87. PAR EPS growth in last 5 year was 7.30%. PAR Technology Corporation (NYSE:PAR) year to date (YTD) performance is -20.81%. PAR Technology Corp. (NYSE:PAR) was selected by Five Guys Burgers and Fries on 27 June, to supply the hardware and software to all 1,200 of its North American restaurant locations.

OvaScience, Inc. (NASDAQ:OVAS) ended the last trading day at $28.49. Company weekly volatility is calculated as 4.78% and price to cash ratio as 4.58. OvaScience, Inc. (NASDAQ:OVAS) showed a weekly performance of 3.49%. Oppenheimer reaffirmed their outperform rating on shares of OvaScience Inc. (NASDAQ:OVAS) in a report issued. They currently have a $60.00 target price on the stock.

Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $57.87. Company weekly volatility is calculated as 1.36% and price to cash ratio as 10.48. Merck & Co. Inc. (NYSE:MRK) showed a weekly performance of 0.56%. On 9 July, Merck & Co. Inc. (NYSE:MRK) declared results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Merck’s substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC).

Leave a Reply

Your email address will not be published. Required fields are marked *